Pulmonary involvement in hepatic disease: an update

Compromiso pulmonar en la enfermedad hepática: una actualización;
Compromisso pulmonar na doença hepática: uma atualização

dc.creatorVásquez Rodríguez, Juan Felipe
dc.creatorYurgaki, James Milton
dc.creatorRada Escobar, Robin
dc.date2017-06-25
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/2925
dc.identifier10.18359/rmed.2925
dc.descriptionLiver disease is a major cause of morbidity and mortality in the world; it is associated with multiple organ involvement. In the lung, three clinical conditions are described; these conditions include, Hepatopulmonary Syndrome (HPS), which is due to a oxygenation defect by the development of pulmonary vascular dilatation. Portopulmonary (HPP) hypertension, it’s mediated by an imbalance between vasodilator and vasoconstrictor agents leading to an increase in mean pulmonary artery pressure and finally the Hydrothorax Liver (HH), that is the least prevalent condition, it’s based on anatomical diaphragm abnormalities, with or without ascites. The presence of SHP or HPP is an independent predictor of mortality, highlighting its importance in the eligibility of patients for orthotopic liver transplantation as a curative measure.
dc.descriptionLa enfermedad Hepática es una causa importante de morbilidad y Mortalidad en el mundo; asociada a compromiso orgánico múltiple. En el pulmón, tres condiciones clínicas han sido descritas; estos cuadros Incluyen, el Síndrome Hepatopulmonar (SHP), que obedece a un trastorno de la oxigenación por dilatación de la vasculatura pulmonar. La hipertensión portopulmonar (HPP), mediada por desequilibrio entre agentes vasodilatadores y vasoconstrictores que conducen a un aumento de la presión media de la arteria pulmonar y por último el Hidrotórax Hepático (HH), que es la condición menos prevalente, se fundamenta principalmente en anomalías anatómicas del diafragma, con o sin relación a la presencia de ascitis. La presencia SHP o HPP es predictor independiente de mortalidad, resaltando su importancia en la elegibilidad de pacientes para trasplante hepático ortotópico como medida curativa. 
dc.description A doença hepatica é uma das principais causas de morbidade e mortalidade no mundo; está associado ao compromisso de vários órgãos. No pulmão, três condições clínicas são descritas;estas condições incluem, Síndrome Hepatopulmonar (HPS), que é devido a um defeito de oxigenação do dilatação vascular pulmonar. A hipertensão portopulmonar (HPP), é mediada por um desequilíbrio entre vasodilatadores e agentes vasoconstritores, levando a um aumento da pressão arterial média da artéria pulmonar e, finalmente, ao hidrotorax hepatico (HH), essa é a condição menos prevalente, é baseada em anormalidades anatômicas do diafragma, com ou sem ascite. A presença de SHP ou HPP é um preditor independente de mortalidade, destacando sua importância na elegibilidade de pacientes para transplante de hepatico como medida curativa.
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/2925/2562
dc.relation/*ref*/Moller, S., et al., Pathophysiological aspects of pulmonary complications of cirrhosis. Scand J Gastroenterol, 2007. 42(4): p. 419-27. https://doi.org/10.1080/00365520601151695
dc.relation/*ref*/Swanson, K.L., R.H. Wiesner, and M.J. Krowka, Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology, 2005. 41(5): p. 1122-9. https://doi.org/10.1002/hep.20658
dc.relation/*ref*/D'Amico, G., G. Garcia-Tsao, and L. Pagliaro, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006. 44(1): p. 217-31. https://doi.org/10.1016/j.jhep.2005.10.013
dc.relation/*ref*/Rehm, J., A.V. Samokhvalov, and K.D. Shield, Global burden of alcoholic liver diseases. J Hepatol, 2013. 59(1): p. 160-8. https://doi.org/10.1016/j.jhep.2013.03.007
dc.relation/*ref*/Scaglione, S., et al., The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol, 2014.
dc.relation/*ref*/Sureka, B., et al., Thoracic perspective revisited in chronic liver disease. Gastroenterol Rep (Oxf), 2015. https://doi.org/10.1093/gastro/gov017
dc.relation/*ref*/Montoya, A., et al., Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev Méd Risaralda, 2014. 20(2): p. 86-94.
dc.relation/*ref*/Machicao, V.I., M. Balakrishnan, and M.B. Fallon, Pulmonary complications in chronic liver disease. Hepatology, 2014. 59(4): p. 1627-37. https://doi.org/10.1002/hep.26745
dc.relation/*ref*/King, P.D., R. Rumbaut, and C. Sanchez, Pulmonary manifestations of chronic liver disease. Dig Dis, 1996. 14(2): p. 73-82. https://doi.org/10.1159/000171540
dc.relation/*ref*/Sen, D.S. and D.G.J. Alexander, Pulmonary complications in liver disease. British Journal of Hospital Medicine, 2009. 70(12): p. 685-691. https://doi.org/10.12968/hmed.2009.70.12.45504
dc.relation/*ref*/Kennedy, T.C. and R.J. Knudson, Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest, 1977. 72(3): p. 305-9. https://doi.org/10.1378/chest.72.3.305
dc.relation/*ref*/Raevens, S., et al., Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver International, 2015. 35(6): p. 1646-1660. https://doi.org/10.1111/liv.12791
dc.relation/*ref*/Grace, J.A. and P.W. Angus, Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol, 2013. 28(2): p. 213-9. https://doi.org/10.1111/jgh.12061
dc.relation/*ref*/Rodríguez-Roisin, R. and M.J. Krowka, Hepatopulmonary Syndrome — A Liver-Induced Lung Vascular Disorder. New England Journal of Medicine, 2008. 358(22): p. 2378-2387. https://doi.org/10.1056/NEJMra0707185
dc.relation/*ref*/Schenk, P., et al., Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology, 2003. 125(4): p. 1042-52. https://doi.org/10.1016/S0016-5085(03)01207-1
dc.relation/*ref*/Singh, C. and J.S. Sager, Pulmonary complications of cirrhosis. Med Clin North Am, 2009. 93(4): p. 871-83, viii. https://doi.org/10.1016/j.mcna.2009.03.006
dc.relation/*ref*/Carter, E.P., et al., Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol, 2002. 283(2): p. L346-53. https://doi.org/10.1152/ajplung.00385.2001
dc.relation/*ref*/Zhang, H.-Y., et al., Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. World Journal of Gastroenterology : WJG, 2007. 13(47): p. 6385-6395. https://doi.org/10.3748/wjg.v13.i47.6385
dc.relation/*ref*/Thorens, J.B. and A.F. Junod, Hypoxaemia and liver cirrhosis: a new argument in favour of a "diffusion-perfusion defect". Eur Respir J, 1992. 5(6): p. 754-6.
dc.relation/*ref*/Rodriguez-Roisin, R., et al., Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J, 2004. 24(5): p. 861-80. https://doi.org/10.1183/09031936.04.00010904
dc.relation/*ref*/Mohammad Alizadeh, A.H., et al., Clinical features of hepatopulmonary syndrome in cirrhotic patients. World J Gastroenterol, 2006. 12(12): p. 1954-6. https://doi.org/10.3748/wjg.v12.i12.1954
dc.relation/*ref*/Lv, Y. and D. Fan, Hepatopulmonary Syndrome. Digestive Diseases and Sciences, 2015. 60(7): p. 1914-1923. https://doi.org/10.1007/s10620-015-3593-0
dc.relation/*ref*/Silverio Ade, O., et al., Are the spider angiomas skin markers of hepatopulmonary syndrome? Arq Gastroenterol, 2013. 50(3): p. 175-9. https://doi.org/10.1590/S0004-28032013000200031
dc.relation/*ref*/Koch, D.G. and M.B. Fallon, Hepatopulmonary syndrome. Clin Liver Dis, 2014. 18(2): p. 407-20. https://doi.org/10.1016/j.cld.2014.01.003
dc.relation/*ref*/Pascasio, J.M., et al., Prevalence and Severity of Hepatopulmonary Syndrome and Its Influence on Survival in Cirrhotic Patients Evaluated for Liver Transplantation. American Journal of Transplantation, 2014. 14(6): p. 1391-1399. https://doi.org/10.1111/ajt.12713
dc.relation/*ref*/Arguedas, M.R., et al., Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol, 2007. 5(6): p. 749-54. https://doi.org/10.1016/j.cgh.2006.12.003
dc.relation/*ref*/Poterucha, J.J., et al., Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology, 1995. 21(1): p. 96-100. https://doi.org/10.1002/hep.1840210117
dc.relation/*ref*/Gupta, S., D. Nayyar, and G. Pomier-Layrargues, Variability of oxygenation in possible hepatopulmonary syndrome: effects of requiring two abnormal arterial blood gas results for diagnosis. Dig Dis Sci, 2015. 60(6): p. 1848-55. https://doi.org/10.1007/s10620-014-3506-7
dc.relation/*ref*/Hopkins, W.E., A.D. Waggoner, and B. Barzilai, Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. Am J Cardiol, 1992. 70(4): p. 516-9. https://doi.org/10.1016/0002-9149(92)91200-N
dc.relation/*ref*/Rollan, M.J., et al., Value of contrast echocardiography for the diagnosis of hepatopulmonary syndrome. Eur J Echocardiogr, 2007. 8(5): p. 408-10. https://doi.org/10.1016/j.euje.2006.07.005
dc.relation/*ref*/Surasi, D., P. Manapragada, and P. Bhambhvani, Lung perfusion imaging in hepatopulmonary syndrome using 99mTc macroaggregated albumin. Journal of Nuclear Cardiology, 2015. 22(3): p. 586-588. https://doi.org/10.1007/s12350-014-9990-5
dc.relation/*ref*/Horvatits, T., et al., Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. J Hepatol, 2014. 61(3): p. 544-9. https://doi.org/10.1016/j.jhep.2014.04.025
dc.relation/*ref*/Fallon, M.B., et al., Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl, 2006. 12(12 Suppl 3): p. S105-7. https://doi.org/10.1002/lt.20971
dc.relation/*ref*/Iyer, V.N., et al., Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology, 2013. 57(6): p. 2427-35. https://doi.org/10.1002/hep.26070
dc.relation/*ref*/Eshraghian, A., A.A.l. Kamyab, and S.K. Yoon, Pharmacological Treatment for Hepatopulmonary Syndrome. BioMed Research International, 2013. 2013: p. 670139.
dc.relation/*ref*/Mantz, F.A., Jr. and E. Craige, Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol, 1951. 52(1): p. 91-7.
dc.relation/*ref*/Simonneau, G., et al., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013. 62(25 Suppl): p. D34-41. https://doi.org/10.1016/j.jacc.2013.10.029
dc.relation/*ref*/Cartin-Ceba, R. and M.J. Krowka, Portopulmonary hypertension. Clin Liver Dis, 2014. 18(2): p. 421-38. https://doi.org/10.1016/j.cld.2014.01.004
dc.relation/*ref*/Aldenkortt, F., et al., Portopulmonary hypertension and hepatopulmonary syndrome. World Journal of Gastroenterology : WJG, 2014. 20(25): p. 8072-8081. https://doi.org/10.3748/wjg.v20.i25.8072
dc.relation/*ref*/Kawut, S.M., et al., Clinical risk factors for portopulmonary hypertension. Hepatology, 2008. 48(1): p. 196-203. https://doi.org/10.1002/hep.22275
dc.relation/*ref*/Krowka, M.J., Portopulmonary hypertension and the issue of survival. Liver Transpl, 2005. 11(9): p. 1026-7. https://doi.org/10.1002/lt.20494
dc.relation/*ref*/Nayak, R., D. Li, and G. Matuschak, Portopulmonary hypertension. Current Gastroenterology Reports, 2009. 11(1): p. 56-63. https://doi.org/10.1007/s11894-009-0009-3
dc.relation/*ref*/Dickinson, M.G., et al., The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol, 2013. 305(1): p. L1-14. https://doi.org/10.1152/ajplung.00031.2013
dc.relation/*ref*/Bosch, J., Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol, 2007. 41 Suppl 3: p. S247-53. https://doi.org/10.1097/MCG.0b013e3181572357
dc.relation/*ref*/Golbin, J.M. and M.J. Krowka, Portopulmonary hypertension. Clin Chest Med, 2007. 28(1): p. 203-18, ix. https://doi.org/10.1016/j.ccm.2006.11.004
dc.relation/*ref*/Hoeper, M.M., M.J. Krowka, and C.P. Strassburg, Portopulmonary hypertension and hepatopulmonary syndrome. The Lancet, 2004. 363(9419): p. 1461-1468. https://doi.org/10.1016/S0140-6736(04)16107-2
dc.relation/*ref*/Ratti, L. and M. Pozzi, The pulmonary involvement in portal hypertension: portopulmonary hypertension and hepatopulmonary syndrome. Gastroenterol Hepatol, 2006. 29(1): p. 40-50. https://doi.org/10.1016/s0210-5705(06)71595-3
dc.relation/*ref*/Torregrosa, M., et al., Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation, 2001. 71(4): p. 572-4. https://doi.org/10.1097/00007890-200102270-00015
dc.relation/*ref*/Galiè, N., et al., Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Vol. 30. 2009. 2493-2537.
dc.relation/*ref*/Troy, P.J. and A.B. Waxman, Portopulmonary Hypertension: Challenges in Diagnosis and Management. Therapeutic Advances in Gastroenterology, 2009. 2(5): p. 281-286. https://doi.org/10.1177/1756283X09338431
dc.relation/*ref*/Swanson, K.L. and M.J. Krowka, Arterial oxygenation associated with portopulmonary hypertension. Chest, 2002. 121(6): p. 1869-75. https://doi.org/10.1378/chest.121.6.1869
dc.relation/*ref*/Krowka, M.J., et al., Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology, 1999. 30(3): p. 641-8. https://doi.org/10.1002/hep.510300307
dc.relation/*ref*/Makisalo, H., et al., Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl, 2004. 10(7): p. 945-50. https://doi.org/10.1002/lt.20153
dc.relation/*ref*/Raevens, S., et al., Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. Eur J Gastroenterol Hepatol, 2013. 25(4): p. 495-502. https://doi.org/10.1097/MEG.0b013e32835c504b
dc.relation/*ref*/Hoeper, M.M., et al., Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J, 2007. 30(6): p. 1096-102. https://doi.org/10.1183/09031936.00032407
dc.relation/*ref*/Krowka, M.J., et al., Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl, 2004. 10(2): p. 174-82. https://doi.org/10.1002/lt.20016
dc.relation/*ref*/Ashfaq, M., et al., The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant, 2007. 7(5): p. 1258-64. https://doi.org/10.1111/j.1600-6143.2006.01701.x
dc.relation/*ref*/Krowka, M.J., et al., Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest, 2012. 141(4): p. 906-15. https://doi.org/10.1378/chest.11-0160
dc.relation/*ref*/Lazaridis, K.N., et al., Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med, 1999. 107(3): p. 262-7. https://doi.org/10.1016/S0002-9343(99)00217-X
dc.relation/*ref*/Emerson, P.A. and J.H. Davies, Hydrothorax complicating ascites. Lancet, 1955. 268(6862): p. 487-8. https://doi.org/10.1016/S0140-6736(55)90269-5
dc.relation/*ref*/Gur, C., Y. Ilan, and O. Shibolet, Hepatic hydrothorax--pathophysiology, diagnosis and treatment--review of the literature. Liver Int, 2004. 24(4): p. 281-4. https://doi.org/10.1111/j.1478-3231.2004.0936.x
dc.relation/*ref*/Lieberman, F.L., et al., Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med, 1966. 64(2): p. 341-51. https://doi.org/10.7326/0003-4819-64-2-341
dc.relation/*ref*/Roussos, A., et al., Hepatic hydrothorax: Pathophysiology diagnosis and management. Journal of Gastroenterology and Hepatology, 2007. 22(9): p. 1388-1393. https://doi.org/10.1111/j.1440-1746.2007.05069.x
dc.relation/*ref*/Haas, A.R. and M.S. Machuzak, Hepatic hydrothorax: current approaches to diagnosis and therapy. Techniques in Gastrointestinal Endoscopy, 2009. 11(3): p. 114-117. https://doi.org/10.1016/j.tgie.2009.06.008
dc.relation/*ref*/Benet, A., et al., Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid. Postgraduate Medical Journal, 1992. 68(796): p. 153-153. https://doi.org/10.1136/pgmj.68.796.153
dc.relation/*ref*/Malagari, K., et al., Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients. Hepatogastroenterology, 2005. 52(62): p. 558-62.
dc.relation/*ref*/Krok, K.L., Hepatic hydrothorax: Current concepts. Clinical Liver Disease, 2014. 4(2): p. 35-37. https://doi.org/10.1002/cld.375
dc.relation/*ref*/Borchardt, J., et al., Treating hepatic hydrothorax. BMJ : British Medical Journal, 2003. 326(7392): p. 751-752. https://doi.org/10.1136/bmj.326.7392.751
dc.relation/*ref*/Rodriguez-Panadero, F. and V.B. Antony, Pleurodesis: state of the art. Eur Respir J, 1997. 10(7): p. 1648-54. https://doi.org/10.1183/09031936.97.10071648
dc.relation/*ref*/Lee, W.J., et al., Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis. Korean J Hepatol, 2011. 17(4): p. 292-8. https://doi.org/10.3350/kjhep.2011.17.4.292
dc.relation/*ref*/Siegerstetter, V., et al., Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol, 2001. 13(5): p. 529-34. https://doi.org/10.1097/00042737-200105000-00011
dc.relation/*ref*/Cerfolio, R.J. and A.S. Bryant, Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg, 2006. 82(2): p. 457-9. https://doi.org/10.1016/j.athoracsur.2006.03.057
dc.relation/*ref*/Rossle, M. and A.L. Gerbes, TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut, 2010. 59(7): p. 988-1000. https://doi.org/10.1136/gut.2009.193227
dc.relation/*ref*/Krishnamoorthy, T.L., M. Taneja, and P.E. Chang, Symptomatic hepatic hydrothorax successfully treated with transjugular intrahepatic portosystemic shunt (TIPS)–role of titration of portosystemic gradient reduction to avoid post-TIPS encephalopathy. Clinical Case Reports, 2014. 2(3): p. 93-97. https://doi.org/10.1002/ccr3.70
dc.rightsDerechos de autor 2017 Revista Med
dc.sourceRevista Med; Vol. 25 No. 1 (2017): january - june; 102-113
dc.sourceRevista Med; Vol. 25 Núm. 1 (2017): enero - junio; 102-113
dc.source1909-7700
dc.source0121-5256
dc.subjectCirrhosis
dc.subjecthepatopulmonary syndrome
dc.subjecthypertension portopulmonary
dc.subjecthydrothorax liver
dc.subjectliver transplantation
dc.subjectCirrosis
dc.subjectsíndrome hepatopulmonar
dc.subjecthipertensión portopulmonar
dc.subjecthidrotórax hepático
dc.subjecttrasplante hepático
dc.subjectCirrose
dc.subjectsíndrome hepatopulmonar
dc.subjecthipertensão portopulmonar
dc.subjecthidrotorax hepatico
dc.subjecttransplante de fígado.
dc.titlePulmonary involvement in hepatic disease: an update
dc.titleCompromiso pulmonar en la enfermedad hepática: una actualización
dc.titleCompromisso pulmonar na doença hepática: uma atualização
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución